Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Abstract
Authors
G. Thompson M. Willis P. Johansen C. Neslusan M. Schroeder I. Girod